Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 61

1.

Efficacy of a Selective Binder of αVβ3 Integrin Linked to the Tyrosine Kinase Inhibitor Sunitinib in Ovarian Carcinoma Preclinical Models.

Sartori A, Corno C, De Cesare M, Scanziani E, Minoli L, Battistini L, Zanardi F, Perego P.

Cancers (Basel). 2019 Apr 13;11(4). pii: E531. doi: 10.3390/cancers11040531.

2.

High Efficacy of Intravenous Gimatecan on Human Tumor Xenografts.

DE Cesare M.

Anticancer Res. 2018 Oct;38(10):5783-5790. doi: 10.21873/anticanres.12917.

PMID:
30275200
3.

Synthesis and Evaluation of the Tumor Cell Growth Inhibitory Potential of New Putative HSP90 Inhibitors.

Bizarro A, Sousa D, Lima RT, Musso L, Cincinelli R, Zuco V, De Cesare M, Dallavalle S, Vasconcelos MH.

Molecules. 2018 Feb 13;23(2). pii: E407. doi: 10.3390/molecules23020407.

4.

Supersulfated low-molecular weight heparin synergizes with IGF1R/IR inhibitor to suppress synovial sarcoma growth and metastases.

Cassinelli G, Dal Bo L, Favini E, Cominetti D, Pozzi S, Tortoreto M, De Cesare M, Lecis D, Scanziani E, Minoli L, Naggi A, Vlodavsky I, Zaffaroni N, Lanzi C.

Cancer Lett. 2018 Feb 28;415:187-197. doi: 10.1016/j.canlet.2017.12.009. Epub 2017 Dec 7.

PMID:
29225052
5.

FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.

Corno C, Stucchi S, De Cesare M, Carenini N, Stamatakos S, Ciusani E, Minoli L, Scanziani E, Argueta C, Landesman Y, Zaffaroni N, Gatti L, Perego P.

Biochem Pharmacol. 2018 Jan;147:93-103. doi: 10.1016/j.bcp.2017.11.009. Epub 2017 Nov 16.

PMID:
29155058
6.

Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat.

Rossini A, Zunino F, Ruggiero G, De Cesare M, Cominetti D, Tortoreto M, Lanzi C, Cassinelli G, Zappasodi R, Tripodo C, Gulino A, Zaffaroni N, Di Nicola M.

Hematol Oncol. 2018 Feb;36(1):360-362. doi: 10.1002/hon.2466. Epub 2017 Jul 21. No abstract available.

PMID:
28730742
7.

Synthesis and Superpotent Anticancer Activity of Tubulysins Carrying Non-hydrolysable N-Substituents on Tubuvaline.

Sani M, Lazzari P, Folini M, Spiga M, Zuco V, De Cesare M, Manca I, Dall'Angelo S, Frigerio M, Usai I, Testa A, Zaffaroni N, Zanda M.

Chemistry. 2017 Apr 27;23(24):5842-5850. doi: 10.1002/chem.201700874. Epub 2017 Apr 12.

PMID:
28300330
8.

1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment.

Ferroni C, Pepe A, Kim YS, Lee S, Guerrini A, Parenti MD, Tesei A, Zamagni A, Cortesi M, Zaffaroni N, De Cesare M, Beretta GL, Trepel JB, Malhotra SV, Varchi G.

J Med Chem. 2017 Apr 13;60(7):3082-3093. doi: 10.1021/acs.jmedchem.7b00105. Epub 2017 Mar 20.

PMID:
28272894
9.

Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism.

El Bezawy R, De Cesare M, Pennati M, Deraco M, Gandellini P, Zuco V, Zaffaroni N.

J Hematol Oncol. 2017 Jan 18;10(1):19. doi: 10.1186/s13045-016-0387-6.

10.

3-Arylidene-N-hydroxyoxindoles: A New Class of Compounds Endowed with Antitumor Activity.

Musso L, Cincinelli R, Zuco V, De Cesare M, Zunino F, Fallacara AL, Botta M, Dallavalle S.

ChemMedChem. 2016 Aug 19;11(16):1700-4. doi: 10.1002/cmdc.201600225. Epub 2016 Jun 17.

11.

Targeting peptidyl-prolyl isomerase pin1 to inhibit tumor cell aggressiveness.

Beretta GL, De Cesare M, Albano L, Magnifico A, Carenini N, Corna E, Perego P, Gatti L.

Tumori. 2016 Mar-Apr;102(2):144-9. doi: 10.5301/tj.5000471. Epub 2016 Feb 19.

PMID:
26917410
12.

Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.

Cincinelli R, Zwick V, Musso L, Zuco V, De Cesare M, Zunino F, Simoes-Pires C, Nurisso A, Giannini G, Cuendet M, Dallavalle S.

Eur J Med Chem. 2016 Apr 13;112:99-105. doi: 10.1016/j.ejmech.2016.02.001. Epub 2016 Feb 3.

13.

CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts.

De Cesare M, Sfondrini L, Pennati M, De Marco C, Motta V, Tagliabue E, Deraco M, Balsari A, Zaffaroni N.

J Transl Med. 2016 Jan 25;14:25. doi: 10.1186/s12967-016-0781-4.

14.

Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.

De Cesare M, Cominetti D, Doldi V, Lopergolo A, Deraco M, Gandellini P, Friedlander S, Landesman Y, Kauffman MG, Shacham S, Pennati M, Zaffaroni N.

Oncotarget. 2015 May 30;6(15):13119-32.

16.

A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides.

Guerrini A, Tesei A, Ferroni C, Paganelli G, Zamagni A, Carloni S, Di Donato M, Castoria G, Leonetti C, Porru M, De Cesare M, Zaffaroni N, Beretta GL, Del Rio A, Varchi G.

J Med Chem. 2014 Sep 11;57(17):7263-79. doi: 10.1021/jm5005122. Epub 2014 Aug 28.

PMID:
25121586
17.

Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals.

Gatti L, Sevko A, De Cesare M, Arrighetti N, Manenti G, Ciusani E, Verderio P, Ciniselli CM, Cominetti D, Carenini N, Corna E, Zaffaroni N, Rodolfo M, Rivoltini L, Umansky V, Perego P.

Oncotarget. 2014 Jun 30;5(12):4516-28.

18.

YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.

Pennati M, Sbarra S, De Cesare M, Lopergolo A, Locatelli SL, Campi E, Daidone MG, Carlo-Stella C, Gianni AM, Zaffaroni N.

Int J Cancer. 2015 Jan 15;136(2):299-309. doi: 10.1002/ijc.28993. Epub 2014 Jun 5.

19.

Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.

Cincinelli R, Musso L, Giannini G, Zuco V, De Cesare M, Zunino F, Dallavalle S.

Eur J Med Chem. 2014 May 22;79:251-9. doi: 10.1016/j.ejmech.2014.04.021. Epub 2014 Apr 8.

20.

miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells.

Pennati M, Lopergolo A, Profumo V, De Cesare M, Sbarra S, Valdagni R, Zaffaroni N, Gandellini P, Folini M.

Biochem Pharmacol. 2014 Feb 15;87(4):579-97. doi: 10.1016/j.bcp.2013.12.009. Epub 2013 Dec 24.

PMID:
24370341

Supplemental Content

Loading ...
Support Center